Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …
Oppenheimer analyst Leland Gershell was out pounding the table on shares of Catalyst Pharmaceuticals (CPRX), reiterating a Buy rating and price target of $6.00, which implies …
Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small …
Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. With that in mind, Cantor …
Hedge fund manager Mitchell J. Blutt of the $1.
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company’s flagship candidate …
Though NDA Gets Stalled, Analyst Says Catalyst “Still on Track”
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced that the first patient has been enrolled into its second Phase 3 clinical trial (designated as LMS-003) to …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors have a smile on their faces Thursday morning, after the small biotech company provided an update on its clinical …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors cheer the news that the biopharmaceutical company has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for …
